Drug Profile
AVA 002
Alternative Names: AVA-002Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Avacta
- Class Antineoplastics; Cystatins; Recombinant proteins
- Mechanism of Action CD3 antigen modulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for research development in Cancer in United Kingdom
- 18 Sep 2018 Avacta has patent protection for Affimer® technology in USA, Europe and Japan (Avacta website, September 2018)
- 07 Sep 2017 Early research in Cancer in United Kingdom (unspecified route) (Avacta pipeline, September 2017)